Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review

Anna M Sawka; Asima Naeem; Jennifer Jones; Julia Lowe; Philip Segal; Jeannette Goguen; Jeremy Gilbert; Afshan Zahedi; Catherine Kelly; Shereen Ezzat

doi:10.1016/j.ecl.2014.02.007

Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review

Endocrinol Metab Clin North Am. 2014 Jun;43(2):475-94. doi: 10.1016/j.ecl.2014.02.007.

Authors

Anna M Sawka¹, Asima Naeem², Jennifer Jones³, Julia Lowe⁴, Philip Segal⁵, Jeannette Goguen⁶, Jeremy Gilbert⁴, Afshan Zahedi⁷, Catherine Kelly⁸, Shereen Ezzat⁹

Affiliations

¹ Division of Endocrinology, Department of Medicine, University Health Network, 200 Elizabeth Street, 12th Floor, Toronto, Ontario M5G 2C4, Canada; Division of Endocrinology, Department of Medicine, University of Toronto, 200 Elizabeth Street, 12 EN-243, Toronto, Ontario M5G 2C4, Canada. Electronic address: Annie.Sawka@uhn.ca.
² Division of Endocrinology, Department of Medicine, University Health Network, 200 Elizabeth Street, 12th Floor, Toronto, Ontario M5G 2C4, Canada.
³ Department of Psychiatry, University of Toronto, 250 College Street, 8th Floor, Toronto, Ontario M5T 1R8, Canada; Cancer Survivorship Program, Princess Margaret Hospital, University Health Network, 200 Elizabeth Street, Bcs-045, Toronto, Ontario M5G 2C4, Canada.
⁴ Division of Endocrinology, Department of Medicine, University of Toronto, 200 Elizabeth Street, 12 EN-243, Toronto, Ontario M5G 2C4, Canada; Division of Endocrinology, Department of Medicine, Sunnybrook Health Sciences Center, 2075 Bayview Avenue, H Wing, Toronto, Ontario M4N 3M5, Canada.
⁵ Division of Endocrinology, Department of Medicine, University Health Network, 200 Elizabeth Street, 12th Floor, Toronto, Ontario M5G 2C4, Canada; Division of Endocrinology, Department of Medicine, University of Toronto, 200 Elizabeth Street, 12 EN-243, Toronto, Ontario M5G 2C4, Canada; Division of Endocrinology, Department of Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.
⁶ Division of Endocrinology, Department of Medicine, University of Toronto, 200 Elizabeth Street, 12 EN-243, Toronto, Ontario M5G 2C4, Canada; Division of Endocrinology, Department of Medicine, St. Michael's Hospital, 61 Queen Street East, 6th Floor, Toronto, Ontario M5C 2T2, Canada.
⁷ Division of Endocrinology, Department of Medicine, University of Toronto, 200 Elizabeth Street, 12 EN-243, Toronto, Ontario M5G 2C4, Canada; Division of Endocrinology, Department of Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada; Division of Endocrinology, Department of Medicine, Women's College Hospital, 76 Grenville Street, Toronto, Ontario M5S 1B2, Canada.
⁸ Division of Endocrinology, Department of Medicine, University of Toronto, 200 Elizabeth Street, 12 EN-243, Toronto, Ontario M5G 2C4, Canada; Division of Endocrinology, Department of Medicine, Women's College Hospital, 76 Grenville Street, Toronto, Ontario M5S 1B2, Canada.
⁹ Endocrine Oncology Site Group, Princess Margaret Hospital, University Health Network, 200 Elizabeth Street, 12NU-1200, Toronto, Ontario M5G 2C4, Canada.

PMID: 24891173
DOI: 10.1016/j.ecl.2014.02.007

Abstract

The relevance of persistent posttreatment fatigue (PPF) to thyroid cancer (TC) survivor populations is not known. This article presents a scoping review, which is an overview of published research activity. Uncontrolled data suggest that PPF is one of the most common complaints in TC survivors. Furthermore, statistically significantly worse levels of fatigue were reported in TC survivors, compared with the general population or healthy controls. There was some inconsistency among PPF risk factors. More research is needed on PPF in TC survivors, including long-term prospective cohort studies, research on fatigue severity prevalence, and randomized controlled trials of treatment strategies.

Keywords: Fatigue; Quality of life; Survivorship; Thyroid cancer; Vitality.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Fatigue / etiology*
Humans
Quality of Life*
Survivors
Thyroid Neoplasms / complications*
Thyroid Neoplasms / therapy*